Coherus director granted RSUs and stock options
Coherus Oncology, Inc. director Jill O'Donnell-Tormey reported equity awards in the form of common stock and stock options.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Coherus Oncology, Inc. director Jill O'Donnell-Tormey reported equity awards in the form of common stock and stock options. She received 30,000 shares of Common Stock as restricted stock units, at no purchase price, with 30,000 shares held directly after this grant.
She was also granted stock options for 60,000 shares of Common Stock with an exercise price of $1.45 per share, expiring on June 5, 2036. According to the footnotes, the 30,000 RSUs vest in full on the one year anniversary of June 3, 2026, and the 60,000 options vest and become exercisable in full on June 3, 2027, in each case subject to her continued service with the company.
Insider Trade Summary
Grant/Award: 90,000 shares
Grant/Award
2 txns
Insider
O'Donnell-Tormey Jill
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 60,000 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 30,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 60,000 contracts (Direct);
Common Stock — 30,000 shares (Direct)
Footnotes (2)
- F1. Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the one year anniversary of June 3, 2026, subject to Reporting Person's continued service relationship with the Issuer on such vesting date.
- F2. The underlying shares vest and become exercisable as to 100% of the total number of the shares subject to the option on June 3, 2027, subject to the Reporting Person's continued service relationship with the Issuer on such vesting date.
Key Figures
RSUs granted: 30,000 shares
Common shares held after grant: 30,000 shares
Stock options granted: 60,000 options
+4 more
7 metrics
RSUs granted
30,000 shares
Restricted stock units, 1 share per RSU, grant on June 5, 2026
Common shares held after grant
30,000 shares
Total Common Stock directly owned following RSU award
Stock options granted
60,000 options
Options on Common Stock granted June 5, 2026
Option exercise price
$1.45 per share
Conversion or exercise price for 60,000 stock options
Option expiration
June 5, 2036
Expiration date of stock options granted
RSU vesting date
one year anniversary of June 3, 2026
100% of RSUs vest on this date, subject to continued service
Option vesting date
June 3, 2027
Options vest and become exercisable in full on this date
Key Terms
restricted stock units ("RSUs"), Stock Option (Right to Buy), exercise price, vesting, +1 more
5 terms
restricted stock units ("RSUs") financial
"Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share..."
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) with underlying security title Common Stock and exercise price of 1.4500..."
exercise price financial
"conversion_or_exercise_price: "1.4500" for the Stock Option (Right to Buy)..."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"100% of the RSUs shall vest on the one year anniversary of June 3, 2026, subject to Reporting Person's continued service..."
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
"expiration_date: "2036-06-05T00:00:00.000Z" for the stock option grant..."
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Coherus Oncology (CHRS) report for Jill O'Donnell-Tormey?
Coherus Oncology reported that director Jill O'Donnell-Tormey received equity awards. She acquired 30,000 shares of Common Stock as restricted stock units and stock options for 60,000 shares, both recorded as grants rather than open-market purchases or sales.
What are the key terms of Jill O'Donnell-Tormey’s stock options in Coherus Oncology (CHRS)?
She received stock options covering 60,000 shares of Common Stock with an exercise price of $1.45 per share. The options expire on June 5, 2036 and vest in full on June 3, 2027, subject to her continued service with the company.
When do Jill O'Donnell-Tormey’s Coherus Oncology (CHRS) RSUs vest?
The restricted stock units vest in full on the one year anniversary of June 3, 2026. Each RSU entitles her to receive one share of Coherus Oncology Common Stock upon vesting, contingent on her continued service relationship with the company on that vesting date.
Are Jill O'Donnell-Tormey’s Coherus Oncology (CHRS) transactions open-market buys or compensation grants?
The transactions are classified as grants or awards, not open-market trades. The Form 4 uses code “A” for both the 30,000-share RSU award and the 60,000-share stock option grant, indicating compensation-related acquisitions rather than purchases or sales in the market.
AI-generated analysis. How Rhea-AI works. Not financial advice.
